Microbiologic Effectiveness Clause Samples

Microbiologic Effectiveness. There are two main producers of hollow-fiber membrane filters: ▇▇▇▇▇▇ and Uzima. The Sawyer7/6B filter was microbiologically tested in its ability to remove Giardia lamblia, Cryptosporidium parvum, and Klebsiella terrigena from surface water (Hydreion, 2005). The testing showed that it removed more than 99.99% of protozoan parasites and over 99.99% of bacteria (Hydreion, 2005). ▇▇▇▇▇▇’▇ PointONE filter does not remove harmful viruses; however, their Point ZeroTWO Purifier is capable of removing such viruses (▇▇▇▇▇▇, 2017). Uzima filters utilize the same technology and have a similar design. BCN Research Laboratories completed microbiological testing of the Uzima Filter model UZ01. The filter was tested to determine its effectiveness at removing the fecal coliforms: Klebsiella pneumoniae, Enterobacter sp., as well as E. coli (BCN Research Laboratories, 2015). Similarly, to the ▇▇▇▇▇▇ brand filter, UZima removed over 99.99% of these pathogens (BCN Research Laboratories, 2015).
View Source

Related to Microbiologic Effectiveness

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be or have been submitted to FDA or other comparable governmental entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, applicable Authorizations, and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and, for studies submitted to regulatory authorities for approval, in all material respects, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete and fairly present the data derived from such studies and trials in all material respects; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes materially call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Tests, Labs, and Imaging and X rays (diagnostic)

  • Staffing Levels To the extent legislative appropriations and PIN authorizations allow, safe staffing levels will be maintained in all institutions where employees have patient, client, inmate or student care responsibilities. In July of each year, the Secretary or Deputy Secretary of each agency will, upon request, meet with the Union, to hear the employees’ views regarding staffing levels. In August of each year, the Secretary or Deputy Secretary of Budget and Management will, upon request, meet with the Union to hear the employees’ views regarding the Governor’s budget request.

  • Measuring DNS parameters Every minute, every DNS probe will make an UDP or TCP “DNS test” to each of the public-­‐DNS registered “IP addresses” of the name servers of the domain name being monitored. If a “DNS test” result is undefined/unanswered, the tested IP will be considered unavailable from that probe until it is time to make a new test.

  • Registry Performance Specifications Registry Performance Specifications for operation of the TLD will be as set forth in Specification 10 attached hereto (“Specification 10”). Registry Operator shall comply with such Performance Specifications and, for a period of at least one (1) year, shall keep technical and operational records sufficient to evidence compliance with such specifications for each calendar year during the Term.